Türkiye’de tianeptinin kötüye kullanım risk yönetimi: Ulusal bir tecrübe

Conclusion: Although tianeptine has several advantages compared with tricyclic antidepressants, it should be carefully observed for abuse potential especially in patients with the history of dependence or abuse of any drug or alcohol.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: Tianeptine is used in the treatment of major depressive episodes and has structural similarities with tricyclic antidepressants although it has different pharmacological properties and has abuse potential among patients with a history of dependence or abuse of any drug or alcohol.

📊

Key Findings & Data:Results: After three individual fatal cases were reported in 2011 and 2012 associated with tianeptine abuse and increased tianeptine abuse reports were received by the risk management department, tianeptine has been included in the controlled substances list in Turkey since October 2012.

💡

Conclusion & Impact:Conclusion: Although tianeptine has several advantages compared with tricyclic antidepressants, it should be carefully observed for abuse potential especially in patients with the history of dependence or abuse of any drug or alcohol.

🔬Design:Research Article

📍Scope:2011 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: Tianeptine is used in the treatment of major depressive episodes and has structural similarities with tricyclic antidepressants although it has different pharmacological properties and has abuse potential among patients with a history of dependence or abuse of any drug or alcohol. In this study, we aimed to evaluate the safety problems and risk management measures for tianeptine in Turkey in relation to its abuse potential. Methods: Adverse event reports noting tianeptine abuse and the risk management measures for use of this agent have been evaluated through retrospective examination of the databases of the Turkish Medicines and Medical Devices Agency, the Intercontinental Medical Statistics (IMS), the Uppsala Monitoring Centre (Vigiflow) and the Turkish Pharmaceuticals Track and Trace System. Results: After three individual fatal cases were reported in 2011 and 2012 associated with tianeptine abuse and increased tianeptine abuse reports were received by the risk management department, tianeptine has been included in the controlled substances list in Turkey since October 2012. Conclusion: Although tianeptine has several advantages compared with tricyclic antidepressants, it should be carefully observed for abuse potential especially in patients with the history of dependence or abuse of any drug or alcohol.

Özet

Amaç: Major depresif atakların tedavisinde kullanılan tianeptin, herhangi bir ilaç veya alkol bağımlılığı veya kötüye kullanımı öyküsü olanlarda bağımlılık potan-siyeli olan ve yapısal olarak trisiklik antidepresanlara benzerlik gösteren, ancak farmakolojik olarak farklıözelliklere sahip bir ilaçtır. Bu çalışmada, Türkiye’detianeptinin kötüye kullanım potansiyelinden doğangüvenlik problemlerini ve alınan risk yönetimi önlemle-rini değerlendirmeyi amaçladık.Yöntemler: Tianeptinin kötüye kullanımıyla ilgili yanetki bildirimleri ve bu ajanla ilgili alınan risk yönetimi önlemleri, Türkiye İlaç ve Tıbbi Cihaz Kurumu UygulamaYazılımı, Sağlık Bilgileri Enstitüsü (IMS) değerleri,Uppsala İzleme Merkezi (Vigiflow) ve Türkiye İlaç TakipSistemi kullanılarak retrospektif olarak değerlendirildi. Bulgular: 2011 ve 2012 yıllarında tianeptinin kötüye kullanımı sonucu meydana gelen üç ölüm vakası ve RiskYönetimi Dairesi’ne tianeptinin kötüye kullanımıyla ilgiliyan etki bildirimlerinin artması neticesinde tianeptin,Türkiye’de 2012 yılının Ekim ayında kontrole tabi ilaçlarlistesine dahil edilmiştir. Sonuç: Tianeptin, diğer trisiklik antidepresanlara görebazı avantajlara sahip olmasına rağmen, bağımlılıkpotansiyeli açısından özellikle herhangi bir ilaç veyaalkol bağımlılığı veya kötüye kullanımı öyküsü olan hastalarda dikkatle izlenmelidir.

🔖

Cite This Article

ARTİRAN, G., KERMAN, S., OZBİLEN, G., KASAP, Y., KOYUNCU, O., AYDINKARAHALİLOGLU, D., YILDIRIM, O., DURMUS, N. (2022). Türkiye’de tianeptinin kötüye kullanım risk yönetimi: Ulusal bir tecrübe. Klinik Psikofarmakoloji Bülteni, Cilt: 23 - Sayı: 2, 149–154. https://ajindex.com/articles/574073

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008;22(1):15-26
Vuković O, Marić NP, Britvić D, Cvetić T, Damjanović A, Prostran M, et al. Efficacy, tolerability and safety of tianeptine in special populations of depressive patients. Psychiatr Danub 2009;21(2):194-8
Drobizhev MI, Syrkin AL, Poltavskaia MG, Pecherskaia MB, Dobrovol’skiĭ AV. Treatment of anxiety-related depression with tianeptine in patients with ischemic heart disease. Zh Nevrol Psikhiatr Im S S Korsakova 2000;100(4):44-7
Vorob’eva OV, Shavlovskaia OA. Coaxil treatment of primary headaches comorbid with depression. Zh Nevrol Psikhiatr Im S S Korsakova 2005;105(1):56-60
Levin OS. Coaxil (tianeptine) in the treatment of depression in Parkinson’s disease. Neurosci Behav Physiol 2007;37(4):419- 24
Saatcioglu O, Erim R, Cakmak D. A case of tianeptine abuse. Turk Psikiyatri Derg 2006;17(1):72-5
Kisa C, Bulbul DO, Aydemir C, Goka E. Is it possible to be dependent to Tianeptine, an antidepressant? A case report. Prog Neuropsychopharmacol Biol Psychiatry 2007 13;31(3):776-8
Hirst C, Cook S, Dai W, Perez-Gutthann S, Andrews E. A call for international harmonization in therapeutic risk management. Pharmacoepidemiol Drug Saf 2006;15(12): 839-49
Lis Y, Roberts MH, Kamble S, J Guo J, Raisch DW. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group. Value Health 2012;15(8):1108-18
Victorri-Vigneau C, Sébille V, Gérardin M, Simon D, Pivette J, Jolliet P. Epidemiological characterization of drug overconsumption: the example of antidepressants. J Addict Dis 2011;30(4):342-50
Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov 2006;1(1):29-41
Malka R, Lôo H, Ganry H, Souche A, Marey C, Kamoun A. Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry Suppl 1992;(15):66-71
Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001;15(3): 231-59
Niederhofer H, Staffen W, Mair A. Tianeptine may be a useful adjunct in the treatment of alcohol dependence of adolescents. Alcohol Clin Exp